Filing Flows › Tvardi Therapeutics (TVRD) › Q1 2025 › vs Q1 2024
Tvardi Therapeutics (TVRD) Q1 2025 vs Q1 2024 (year over year)
Tvardi Therapeutics's revenue rose $434K (+20%) from $2.1M in Q1 2024 to $2.6M in Q1 2025. The biggest changes: Other revenue +$700K (+112%); Collaborative revenue +$410K (+52%); Clinical compound revenue −$36K (-43%).
Tvardi Therapeutics, Q1 2025: revenue $2.6M (+20% year over year), operating margin -92.9%, net loss $4.9M, operating cash flow −$4.7M. The chart draws each line against Q1 2024, the increases inside each band.
Every line
| Line | Q1 2025 | Q1 2024 | Change | % |
|---|---|---|---|---|
| Other revenue | $1.3M | $623K | $700K | +112% |
| Collaborative revenue | $1.2M | $788K | $410K | +52% |
| Clinical compound revenue | $48K | $84K | −$36K | -43% |
| Revenue | $2.6M | $2.1M | $434K | +20% |
| Net loss | $4.9M | $30.7M | −$25.8M | -84% |
| Costs & expenses | $7.5M | $32.8M | −$25.4M | -77% |
| Operating costs | $5.0M | $31.8M | −$26.8M | -84% |
| Interest & other, net | $2.5M | $1.0M | $1.5M | +145% |
| Research & development | $319K | $22.0M | −$21.6M | -99% |
| General & admin | $4.6M | $6.8M | −$2.2M | -32% |
| Operating cash sources | $6.1M | $33.8M | −$27.7M | -82% |
| Share-based compensation | $1.4M | $3.3M | −$1.9M | -57% |
| Cash used in operations | $4.7M | $30.5M | −$25.8M | -85% |
| Net loss absorbed | $4.9M | $30.7M | −$25.8M | -84% |
| Working capital & other | $1.2M | $3.1M | −$1.9M | -61% |
Questions
How much did Tvardi Therapeutics's revenue grow year over year in Q1 2025?
Tvardi Therapeutics's revenue rose $434K (+20%) from $2.1M in Q1 2024 to $2.6M in Q1 2025.
What drove Tvardi Therapeutics's revenue change in Q1 2025?
Other revenue +$700K (+112%); Collaborative revenue +$410K (+52%); Clinical compound revenue −$36K (-43%).